{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "68682-580",
      "generic_name": "Bupropion Hydrobromide",
      "labeler_name": "Oceanside Pharmaceuticals",
      "brand_name": "Bupropion Hydrobromide",
      "active_ingredients": [
        {
          "name": "BUPROPION HYDROBROMIDE",
          "strength": "174 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "68682-580-30",
          "description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68682-580-30)",
          "marketing_start_date": "20260629",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {
        "manufacturer_name": [
          "Oceanside Pharmaceuticals"
        ],
        "rxcui": [
          "993550",
          "993567",
          "993681"
        ],
        "spl_set_id": [
          "3ec04240-baef-44d7-8d73-a181171eec43"
        ],
        "is_original_packager": [
          true
        ],
        "unii": [
          "E70G3G5863"
        ]
      },
      "marketing_category": "NDA AUTHORIZED GENERIC",
      "dosage_form": "TABLET, EXTENDED RELEASE",
      "spl_id": "361893cf-be64-4b2c-a70e-e3ba68e69309",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20260629",
      "product_id": "68682-580_361893cf-be64-4b2c-a70e-e3ba68e69309",
      "application_number": "NDA022108",
      "brand_name_base": "Bupropion Hydrobromide",
      "pharm_class": [
        "Aminoketone [EPC]",
        "Dopamine Uptake Inhibitors [MoA]",
        "Increased Dopamine Activity [PE]",
        "Increased Norepinephrine Activity [PE]",
        "Norepinephrine Uptake Inhibitors [MoA]"
      ]
    }
  ]
}